Search Results | Diabetes Care | American Diabetes Association

1-20 of 77

2 3 4

Sort by

Sort Order Select

Journal Articles

Postintervention Effects of Varying Treatment Arms on Glycemic Failure and β-Cell Function in the TODAY Trial

The TODAY Study Group

Diabetes Care 2021;44(1):75–80

DOI: https://doi.org/10.2337/dc20-0622

Published: 10 November 2020

View article

Journal Articles

Changes in Visceral and Subcutaneous Fat in Youth With Type 2 Diabetes in the TODAY Study

Ruban Dhaliwal, John A. Shepherd, Laure El ghormli, Kenneth C. Copeland, Mitchell E. Geffner, Janine Higgins, Lynne L. Levitsky, Kristen J. Nadeau, Ruth S. Weinstock, Neil H. White

Diabetes Care 2019;42(8):1549–1559

DOI: https://doi.org/10.2337/dc18-1935

Published: 05 June 2019

View article

Includes: Supplementary data

Journal Articles

CYP2C8 and SLCO1B1 Variants and Therapeutic Response to Thiazolidinediones in Patients With Type 2 Diabetes

Adem Y. Dawed, Louise Donnelly, Roger Tavendale, Fiona Carr, Graham Leese, Colin N.A. Palmer, Ewan R. Pearson, Kaixin Zhou

Diabetes Care 2016;39(11):1902–1908

DOI: https://doi.org/10.2337/dc15-2464

Published: 06 June 2016

View article

Includes: Supplementary data

Journal Articles

The Pharmacogenetics of Type 2 Diabetes: A Systematic Review

Nisa M. Maruthur, Matthew O. Gribble, Wendy L. Bennett, Shari Bolen, Lisa M. Wilson, Poojitha Balakrishnan, Anita Sahu, Eric Bass, W.H. Linda Kao, Jeanne M. Clark

Diabetes Care 2014;37(3):876–886

DOI: https://doi.org/10.2337/dc13-1276

Published: 11 February 2014

View article

Includes: Supplementary data

Journal Articles

Metformin, but Not Rosiglitazone, Attenuates the Increasing Plasma Levels of a New Cardiovascular Marker, Fibulin-1, in Patients With Type 2 Diabetes

Vibe Skov, Claudia Cangemi, Jeppe Gram, Mette M. Christensen, Ellen Grodum, Ditte Sørensen, W. Scott Argraves, Jan E. Henriksen, Lars M. Rasmussen

Diabetes Care 2014;37(3):760–766

DOI: https://doi.org/10.2337/dc13-1022

Published: 11 February 2014

View article

Journal Articles

Validity of Meta-analysis in Diabetes: We Need to Be Aware of Its Limitations

Philip D. Home, DM, DPHIL

Diabetes Care 2013;36(10):3361–3367

DOI: https://doi.org/10.2337/dc12-2449

Published: 14 September 2013

View article

Journal Articles

The Effect of Intensive Glucose Lowering on Lipoprotein Particle Profiles and Inflammatory Markers in the Veterans Affairs Diabetes Trial (VADT)

Juraj Koska, MD, Aramesh Saremi, MD, Gideon Bahn, PHD, Shizuya Yamashita, MD, Peter D. Reaven, MD, for the Veterans Affairs Diabetes Trial Investigators

Diabetes Care 2013;36(8):2408–2414

DOI: https://doi.org/10.2337/dc12-2082

Published: 11 July 2013

View article

Includes: Supplementary data

Journal Articles

Treatment Effects on Measures of Body Composition in the TODAY Clinical Trial

TODAY Study Group

Diabetes Care 2013;36(6):1742–1748

DOI: https://doi.org/10.2337/dc12-2534

Published: 15 May 2013

View article

Includes: Supplementary data

Journal Articles

Safety and Tolerability of the Treatment of Youth-Onset Type 2 Diabetes: The TODAY experience

TODAY Study Group

Diabetes Care 2013;36(6):1765–1771

DOI: https://doi.org/10.2337/dc12-2390

Published: 15 May 2013

View article

Includes: Supplementary data

Journal Articles

Approaches to Treatment of Type 2 Diabetes

Zachary T. Bloomgarden, MD

Diabetes Care 2008;31(8):1697–1703

DOI: https://doi.org/10.2337/dc08-zb08

Published: 01 August 2008

View article

Journal Articles

Rosiglitazone and Risk of Cancer: A meta-analysis of randomized clinical trials

Matteo Monami, MD, PHD, Caterina Lamanna, MD, Niccolò Marchionni, MD, Edoardo Mannucci, MD

Diabetes Care 2008;31(7):1455–1460

DOI: https://doi.org/10.2337/dc07-2308

Published: 01 July 2008

View article

Includes: Supplementary data

Journal Articles

Rosiglitazone-Associated Fractures in Type 2 Diabetes: An analysis from A Diabetes Outcome Progression Trial (ADOPT)

Steven E. Kahn, MB, CHB, Bernard Zinman, MD, John M. Lachin, SCD, Steven M. Haffner, MD, William H. Herman, MD, Rury R. Holman, MD, Barbara G. Kravitz, MS, Dahong Yu, PHD, Mark A. Heise, PHD, R. Paul Aftring, MD, PHD, Giancarlo Viberti, MD, for the A Diabetes Outcome Progression Trial (ADOPT) Study Group

Diabetes Care 2008;31(5):845–851

DOI: https://doi.org/10.2337/dc07-2270

Published: 01 May 2008

View article

Includes: Supplementary data

Journal Articles

Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose: Results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial

The DREAM Trial Investigators

Diabetes Care 2008;31(5):1007–1014

DOI: https://doi.org/10.2337/dc07-1868

Published: 01 May 2008

View article

Journal Articles

The Rosigliazone Meta-Analysis: Lessons for the future

Jonathan J. Shuster, PHD, Desmond A. Schatz, MD

Diabetes Care 2008;31(3):e10

DOI: https://doi.org/10.2337/dc07-2147

Published: 01 March 2008

View article

Journal Articles

Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: Update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

David M. Nathan, MD, John B. Buse, MD, PHD, Mayer B. Davidson, MD, Ele Ferrannini, MD, Rury R. Holman, FRCP, Robert Sherwin, MD, Bernard Zinman, MD

Diabetes Care 2008;31(1):173–175

DOI: https://doi.org/10.2337/dc08-9016

Published: 01 January 2008

View article

Journal Articles

Lessons From the Avandia Controversy: A new paradigm for the development of drugs to treat type 2 diabetes

Robert I. Misbin, MD

Diabetes Care 2007;30(12):3141–3144

DOI: https://doi.org/10.2337/dc07-1908

Published: 01 December 2007

View article

Journal Articles

Pioglitazone and Rosiglitazone Have Different Effects on Serum Lipoprotein Particle Concentrations and Sizes in Patients With Type 2 Diabetes and Dyslipidemia

Mark A. Deeg, MD, John B. Buse, MD, Ronald B. Goldberg, MD, David M. Kendall, MD, Anthony J. Zagar, MS, Scott J. Jacober, DO, Mehmood A. Khan, MD, Alfonzo T. Perez, MD, Meng H. Tan, MD, on behalf of the GLAI Study Investigators

Diabetes Care 2007;30(10):2458–2464

DOI: https://doi.org/10.2337/dc06-1903

Published: 01 October 2007

View article

Journal Articles

Beneficial Effects of Combined Treatment With Rosiglitazone and Exercise on Cardiovascular Risk Factors in Patients With Type 2 Diabetes

Nikolaos P.E. Kadoglou, MD, Fotios Iliadis, MD, Christos D. Liapis, MD, FACS, FRCS, Despina Perrea, PHD, Nikoleta Angelopoulou, MD, Miltiadis Alevizos, MD

Diabetes Care 2007;30(9):2242–2244

DOI: https://doi.org/10.2337/dc07-0341

Published: 01 September 2007

View article

Journal Articles

The Avandia Debate

Zachary T. Bloomgarden, MD

Diabetes Care 2007;30(9):2401–2408

DOI: https://doi.org/10.2337/dc07-zb09

Published: 01 September 2007

View article

Journal Articles

Thiazolidinedione Treatment Decreases Bone Mineral Density in Type 2 Diabetic Men

Subhashini Yaturu, MD, Barbara Bryant, BS, Sushil K. Jain, PHD

Diabetes Care 2007;30(6):1574–1576

DOI: https://doi.org/10.2337/dc06-2606

Published: 01 June 2007

View article

2 3 4

NARROW

Postintervention Effects of Varying Treatment Arms on Glycemic Failure and β-Cell Function in the TODAY Trial

Changes in Visceral and Subcutaneous Fat in Youth With Type 2 Diabetes in the TODAY Study

CYP2C8 and SLCO1B1 Variants and Therapeutic Response to Thiazolidinediones in Patients With Type 2 Diabetes

The Pharmacogenetics of Type 2 Diabetes: A Systematic Review

Metformin, but Not Rosiglitazone, Attenuates the Increasing Plasma Levels of a New Cardiovascular Marker, Fibulin-1, in Patients With Type 2 Diabetes

Validity of Meta-analysis in Diabetes: We Need to Be Aware of Its Limitations

The Effect of Intensive Glucose Lowering on Lipoprotein Particle Profiles and Inflammatory Markers in the Veterans Affairs Diabetes Trial (VADT)

Treatment Effects on Measures of Body Composition in the TODAY Clinical Trial

Safety and Tolerability of the Treatment of Youth-Onset Type 2 Diabetes: The TODAY experience

Approaches to Treatment of Type 2 Diabetes

Rosiglitazone and Risk of Cancer: A meta-analysis of randomized clinical trials

Rosiglitazone-Associated Fractures in Type 2 Diabetes: An analysis from A Diabetes Outcome Progression Trial (ADOPT)

Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose: Results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial

The Rosigliazone Meta-Analysis: Lessons for the future

Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: Update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

Lessons From the Avandia Controversy: A new paradigm for the development of drugs to treat type 2 diabetes

Pioglitazone and Rosiglitazone Have Different Effects on Serum Lipoprotein Particle Concentrations and Sizes in Patients With Type 2 Diabetes and Dyslipidemia

Beneficial Effects of Combined Treatment With Rosiglitazone and Exercise on Cardiovascular Risk Factors in Patients With Type 2 Diabetes

The Avandia Debate

Thiazolidinedione Treatment Decreases Bone Mineral Density in Type 2 Diabetic Men

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only